Abstract
We studied BRL 25000,(amoxicillin trihydrate and potassium clavulanate a β-lactamase inhibitor in ratio of 2: 1), in the otorhinolaryngological field in terms of its basic and clinical utility.
1. Pharmacokinetics
The distribution of BRL 25000 in mucous membrane of maxillary sinus and retaining liquid of maxillary sinus after administration of 1 tablet (375 mg) was favorable and the good transitional properties were obtained. It was similar to chepherns.
2. Clinical results
BRL 25000 was administered to 26 patients (6 cases with otitis media, 9 cases with tonsillitis, 2 cases with sinusitis, 1 case with laryngitis, 5 cases with pharyngitis, 1 case with epipharyngitis and 2 cases with pharyngolaryngitis). The overall clinical effective response was obtained in 88.5% of patients.
3. Bacteriological effects
BRL 25000 was effe ctive against amoxicillin-resistant S. aureus and K. rhinoscleromatis.
4. Side effects
No adverse reactions were seen.
